Patent intelligence · CA
CA 3183290
COMPRIME COMPRENANT DE L'OPICAPONE
COMPRIME COMPRENANT DE L'OPICAPONE
Patent details — CA 3183290
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Dec 2, 2021
- Expiration
- Nov 27, 2041
- Applicant
- ONO PHARMACEUTICAL CO [JP]
- CPC classes
- A61K 9/ 14 A I, A61K 9/ 20 A I, A61K/314439, A61K/9143
Quick answer
CA 3183290 (COMPRIME COMPRENANT DE L'OPICAPONE) is held by ONO PHARMACEUTICAL CO [JP]. Status: granted. Granted Dec 2, 2021. Expires Nov 27, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ONO PHARMACEUTICAL CO [JP]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 14 A I, A61K 9/ 20 A I, A61K/314439, A61K/9143, A61K/92009, A61K/92013
More from ONO PHARMACEUTICAL CO [JP]
Related pharmaceutical patents in our USPTO index.
-
WO 2026106499
ANTAGONISTES DU RÉCEPTEUR DE L'ORÉXINE : COMPOSÉS 2-AZABICYCLIQUES
granted -
WO 2026015039
THÉRAPIE GÉNIQUE POUR LE TRAITEMENT DE L'ENCÉPHALOPATHIE ÉPILEPTIQUE ASSOCIÉE À LA SYNGAP1
granted -
WO 2025211975
AGONISTES DU RÉCEPTEUR DE L'OREXINE
granted -
WO 2025023852
ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE MORPHOLINE
granted -
WO 2025023851
ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE MORPHOLINE
granted -
WO 2024242579
RÉGIMES DE TRAITEMENT DE LA MALADIE DE PARKINSON IDIOPATHIQUE PRÉCOCE
granted -
AU 2023244944
PRODRUGS OF OPICAPONE
granted -
WO 2024039256
RÉGIMES THÉRAPEUTIQUES POUR LA MALADIE DE PARKINSON
granted
Frequently asked questions
What is US patent 3183290?
CA 3183290 (COMPRIME COMPRENANT DE L'OPICAPONE) is held by ONO PHARMACEUTICAL CO [JP]. Status: granted. Granted Dec 2, 2021. Expires Nov 27, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 3183290?
ONO PHARMACEUTICAL CO [JP] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does CA 3183290 expire?
Our index shows an expiration date of Nov 27, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.